The Journal of rheumatologyJul 7, 2026

Influencing Metabolism and Inflammation in Psoriasis and Psoriatic Arthritis Using Diet, Diabetes Drugs, and Patient Views

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 8, 2026

Abstract

Patients with psoriasis and psoriatic arthritis often experience obesity, type 2 diabetes, and metabolic syndrome, which can lead to worsened outcomes.

Dietary interventions may improve symptoms and metabolic profiles in patients with psoriasis and psoriatic arthritis.
Anti-inflammatory and low-calorie diets are associated with enhancements in health status.
Glucagon-like peptide 1 receptor agonists may offer both metabolic and immune system benefits for those with psoriasis and psoriatic arthritis.
Early evidence suggests potential advantages of glucagon-like peptide 1 receptor agonists, though findings are preliminary and based on small studies.
Patients value holistic care strategies that address comorbidities and enhance quality of life.

Simplified

Patients with psoriasis (PsO) and psoriatic arthritis (PsA) frequently present with obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, all of which worsen outcomes and reduce treatment response. Dietary interventions represent one strategy to address this interplay, targeting the microbiome, metabolome, and joint inflammation. Antiinflammatory and hypocaloric diets improve symptoms and metabolic profiles. In parallel, glucagon-like peptide 1 receptor agonists (GLP-1RAs), originally approved for T2DM and obesity, have emerged as promising agents with both metabolic and immunomodulatory effects. Early reports in PsO and PsA suggest potential benefit, though evidence remains preliminary and based on small, heterogeneous studies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Patient Research Partner (PRP) initiative highlights that people living with psoriatic disease (PsD) value holistic strategies that address comorbidities, improve quality of life, and support shared decision making. Most patients attempted lifestyle changes, yet common barriers included fatigue, lack of motivation, and absence of specific recommendations from treating physicians. Together, dietary approaches, GLP-1RAs, and patient-informed priorities underscore the potential of multidisciplinary, collaborative care to optimize outcomes in PsD.

Full Text

Full text is available at the source.

View Full Text ↗

Influencing Metabolism and Inflammation in Psoriasis and Psoriatic Arthritis Using Diet, Diabetes Drugs, and Patient Views

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief